Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates

Molecules- Switzerland

doi 10.3390/molecules201119664

Full Text

Abstract

Available in

Date

Authors

Publisher

MDPI AG

Related search

Phase I Study of Chimeric Anti-Cd20 Monoclonal Antibody in Chinese Patients With CD20-positive Non-Hodgkin’s Lymphoma

Chinese Journal of Cancer Research
Cancer ResearchOncology
2016English

Targeted Alpha-Therapy Using [Bi-213]anti-Cd20 as Novel Treatment Option for Radio- And Chemoresistant Non-Hodgkin Lymphoma Cells

Oncotarget
Oncology
2013English

Antibody-Targeted Paclitaxel Loaded Nanoparticles for the Treatment of CD20+ B-Cell Lymphoma

Scientific Reports
Multidisciplinary
2017English

Peptide–drug Conjugates as Effective Prodrug Strategies for Targeted Delivery

Advanced Drug Delivery Reviews
Pharmaceutical Science
2017English

Improving the Treatment of Non-Hodgkin Lymphoma With Antibody-Targeted Radionuclides

Cancer
Cancer ResearchOncology
2010English

Treatment of Graves' Disease and Associated Ophthalmopathy With the Anti-Cd20 Monoclonal Antibody Rituximab: An Open Study

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2007English

Characterization of Novel Murine Anti-Cd20 Monoclonal Antibodies and Their Comparison to 2B8 and C2B8 (Rituximab)

International Journal of Oncology
Cancer ResearchOncology
2007English

T Cell Immunity to Lymphoma Following Treatment With Anti-Cd40 Monoclonal Antibody

Journal of Immunology
AllergyImmunology
2002English

Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-Egfr and Anti-Vegf Molecules

Current Drug Metabolism
Clinical BiochemistryPharmacology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy